Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.60p -2.68% 21.80p 20.00p 21.00p 22.50p 20.50p 22.50p 624,424 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -7.2 -4.5 - 44.62

Futura Medical Share Discussion Threads

Showing 16176 to 16195 of 16825 messages
Chat Pages: Latest  649  648  647  646  645  644  643  642  641  640  639  638  Older
DateSubjectAuthorDiscuss
08/1/2019
09:47
I certainly see this heading back to the 40's quite fast.Will it get taken over before shareholders can reap the real rewards has always been my main concern.This was manipulated down to crazy levels,but by who?One of the potential licencees?
j777j
08/1/2019
09:42
not selling a single share untill it hit 50p minimum i wouldnt surprised if FUM gets bought because of its low valuation . sorry getting a little euphoric here but stock has really monster upside potential
ih_572003
08/1/2019
08:51
this microcap company valued at laughable 18 million hold a potential MULTI BILLION DOLLAR DRUG thats unbelievable . you will not find a such heavily underpriced stock out there like FUM thats for sure . £2+ tgt by year end.GLTA Research Confirms MED2002's US$1 Billion Potential hxxps://futuramedical.com/content/news/archive17/060317b.asp The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time. Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide. Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life. Almost half of all outstanding shares held only by a few Institutional investors which is a great sign Lombard Odier Asset Management (Europe) Ltd. 49 080 631 T. Adams 14 439 418 Robin Anthony Lamb 9 571 873 W.T. Lamb Holdings Ltd. 9 176 891 Hargreaves Lansdown Stockbrokers Ltd. 8 249 000 Octopus Investments Ltd. 6 450 778 Hargreaves Lansdown Asset Management Ltd. 5 173 000 Medinvest Holdings Ltd. 4 222 003 Christopher John Crabtree 3 398 000 Investec Wealth & Investment Ltd. 3 301 000
ih_572003
08/1/2019
08:24
rallyyyyyyyyyyyy 20p by end of this month yippiiiii
ih_572003
08/1/2019
08:07
starting in green again ,this undiscovered stock needs more pr once the investors get notice of this goldmine then it will skyrocketing . send some emails to large pharmas to look into this one lets see what happens .
ih_572003
08/1/2019
07:38
back to 40-50p range before approval of tpr100 next quarter even buyout is possible because of its low valuation
ih_572003
07/1/2019
21:37
im sorry for those who bought at high a few years ago but at that time FUMs most promosing drug MED was in early stage so you guys bought to early . Now is a different time because we are much closer to Phase 3 results of MED and Approval of TPR100 thats why i think FUM is a super hot opportunity at current share price .We are talking about a company which cost only £16 million thats nothing for a company with a potential multi billion dollar drug . Like J777J said its still time to average down at this dirt low price .GLTA
bioking
07/1/2019
19:24
Many long suffering shareholders will stop banging on about the past,look at where the co is now and add to holdings at these crazy low prices.
j777j
07/1/2019
15:57
this 15 million company could be the next GSK in the coming years ..love the potential here miracle erectile dysfunction gel 12 times faster than viagra contains explosive https://www.youtube.com/watch?v=bRpv5N0zOXQ
ih_116147
07/1/2019
15:48
its an article by proactiveinvestors ,i posted the link but i dont know why it doesnt work here . copy and paste the headline and google it
ih_116147
07/1/2019
15:34
A link would be helpful but I suspect that none exists.
joestalin
07/1/2019
15:30
ih "Most doctors think Futura’s erectile dysfunction gel is an improvement on Viagra and Cialis [...]" I hope you are right but where is that stated, please?
dontshoutatonce
07/1/2019
15:08
did i say rally before No okay RALLYYYYYYYYYYYYYYYY and stock is still massive undervalued at around 16 million valaution .I LOVE ITTTTT
ih_116147
07/1/2019
14:23
FUM = market cap 15 million / Cash $10 million / 1 MEGA Blockbuster in phase 3 + 1 Product (CSD500) approved in Europa and many other Countries outside of EU and another 1 Drug (TPR100) awaiting Approval = A LIFETIME OPP i dont like to call such numbers but this stock really has 20 BAGGER potential .good luck all
ih_116147
07/1/2019
13:06
For those wondering what the risks with taking NSAIDs are..."Except for aspirin, all over-the-counter NSAIDs now must carry a warning about the risks of heart attack and stroke along with other side effects. NSAIDshave other dangers, too. They can cause high blood pressure and kidney damage in some people."So Futura have a topical pain medication that not only works much faster than all the competition, but is much safer as is applied topically.
j777j
07/1/2019
12:55
These studies showed that TPR100 achieved up to 40 times higher bioavailability than those achieved by other commercially available products with none of the side effects which can be seen with oral NSAID products.Plus the dosage can be halved from 4x daily to 2x.Another winning proposition in a market 3x larger than the ED market.
j777j
07/1/2019
12:44
RALLYYYYYYYYYYYYYYYY 20p here we come hehehe i love this stock Respondents indicated the rapid onset of action, an average of less than five minutes, was the key feature and could command a price premium compared with existing treatments such as Viagra and Cialis, which have a substantially slower onset. That made it 'highly differentiated' from the rivals. Ipsos, which a strong record in forecasting drug sales, predicts peak OTC or without prescription annual sales for MED2002 in excess of US$650mln, of which 70% would be in addition to previous estimates of a US$600mln prescription market. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions would be more than US$1bn under patent.
ih_116147
07/1/2019
12:43
Yes and its will likely become preferred over taking a pill.The pain gel market is even larger than the erectile dysfunction market.
j777j
07/1/2019
12:31
If you were a serious investor you would cost average.
j777j
07/1/2019
12:29
I got excited with FUM and bought too many about 12-14 months ago. My average buy price is around 40p! So I'm in a similar situation to MTB - just not worth selling and hoping for some action.
2cbg
Chat Pages: Latest  649  648  647  646  645  644  643  642  641  640  639  638  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190520 22:25:01